Real-world evidence is helping improve HER2-low metastatic breast cancer care, identify treatment gaps, and better understand patient distress and outcomes.
Jessica Paulus, ScD
Advertisement
Articles by Jessica Paulus, ScD
Jessica Paulus, ScD, discusses emerging real-world evidence suggesting GLP-1 receptor agonists may be associated with improved survival outcomes across several cancer types, while emphasizing the need for prospective clinical research.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
2
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
3
FDA Accepts NDA for AD109 to Treat of Adults With Obstructive Sleep Apnea
4
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
5